Sign In
Buy IDXG
$1.75
-0.0100 (-0.568%)
At Close: Jun 03, 2026
Analysts Offer Insights on Healthcare Companies: Rockwell Med (NASDAQ: RMTI) and Motus Gi Holdings (NASDAQ: MOTS)
11:10am, Tuesday, 21'st Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rockwell Med (
RMTI
–
Research Report
) and Motus Gi Holdings (
MOTS
–
Research Report
) with bulli
Coronavirus Scare Supports These Biotech ETFs & Stocks
12:00am, Tuesday, 24'th Mar 2020
Stocks Analysis by Zacks Investment Research covering: S&P 500, Dow Jones Industrial Average, Gilead Sciences Inc, Biogen Inc. Read Zacks Investment Research's latest article on Investing.com
Mar 18, 2020 (The Expresswire) --
Global “Hospital Acquired Infections (HAI) Diagnostics Market” Report 2020 is a comprehensive, professional report provides...
Interpace Diagnostics Group (NASDAQ:IDXG) and LeMaitre Vascular (NASDAQ:LMAT) Head-To-Head Analysis
07:54am, Saturday, 14'th Mar 2020
Interpace Diagnostics Group (NASDAQ:IDXG) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the s
Interpace Diagnostics Issues Update Regarding Announced Contract with BCBS of Massachusetts
01:25am, Thursday, 12'th Mar 2020
Interpace Diagnostics, a subsidiary of Interpace Biosciences (IDXG) announced today that it has entered into a contract with Blue Cross Blue Shield of Massachusetts. While terms of this Agreement are
Interpace Diagnostics Announces Contract with BCBS of Massachusetts
10:55am, Tuesday, 10'th Mar 2020
Interpace Diagnostics, a subsidiary of Interpace Biosciences (IDXG) announced today that it has entered into a contract with Blue Cross Blue Shield of Massachusetts with over 3 million members in Mass
Interpace Biosciences Announces Acceptance of first paper Demonstrating Clinical Performance of ThyGeNEXT with ThyraMIR
11:55am, Monday, 02'nd Mar 2020
The article, entitled “Clinical performance of multiplatform mutation panel and microRNA risk classifier in indeterminate thyroid nodules”, will be published online in the coming weeks. The peer-
Interpace Announces Extension of LabCorp Agreement
11:55am, Monday, 24'th Feb 2020
Interpace Biosciences, Inc. (IDXG) announced today that its agreement with LabCorp® (LH) has been extended for an additional two years, through January 2022. Interpace and LabCorp initially entered
Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay
11:55am, Tuesday, 11'th Feb 2020
Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement for Interpace Diagnostics’ ThyraMIR® miRNA classi
Interpace Biosciences Announces Addition to Board of Directors and Changes in Leadership
11:55am, Thursday, 30'th Jan 2020
Ron Rocca, CEO of Exagen, appointed to BoardJames Early, CFO announces retirement; Fred Knechtel, formerly CFO of GENEWIZ, appointed as CFOJeff Salzman, formerly of CareDX,.
Interpace Diagnostics Group (NASDAQ:IDXG) & ICU Medical (NASDAQ:ICUI) Critical Contrast
08:54am, Thursday, 16'th Jan 2020
Interpace Diagnostics Group (NASDAQ:IDXG) and ICU Medical (NASDAQ:ICUI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their d
Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital and Ampersand Capital Partners
11:55am, Monday, 13'th Jan 2020
1315 Capital and Ampersand are two leading private equity firms investing in laboratory services. The new Series B Preferred Stock investment will be convertible into common stock at a conversion pri
Edited Transcript of IDXG earnings conference call or presentation 13-Nov-19 9:30pm GMT
12:33pm, Wednesday, 08'th Jan 2020
Q3 2019 Interpace Diagnostics Group Inc Earnings Call
Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subsidiary, Interpace Diagnostics has entered into a collabor
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®
11:55am, Tuesday, 17'th Dec 2019
Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage determination (LCD) for the Company’s ThyGeNEXT®
